Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on September 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 10 to 11 directors with Anne C. Whitaker appointed through the 2027 annual meeting.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 11 directors with Anne C. Whitaker appointed through the 2027 annual meeting
- $600,000 initial equity award, split equally between stock options and restricted stock units
- Equity award vests in three equal annual installments, subject to continuous service
- Standard annual cash retainer and equity grant apply under Alkermes’ director compensation policy
- No board committee assignment disclosed; indemnification agreements executed
Item 7.01 · Regulation FD Disclosure
- Susan Whitaker appointed to Alkermes’ Board of Directors
- Board composition change may influence governance, oversight, and strategic direction
- Press release details furnished in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Anne C. Whitaker appointed independent director, strengthening board expertise in biopharmaceutical commercialization and operations
- Extensive CEO and public-company board experience adds strategic oversight as Alkermes advances neuroscience pipeline
- Current board roles at Basilea Pharmaceutica Ltd and ICON plc may broaden industry and healthcare-network perspectives
- Appointment supports Alkermes’ growth and transformation strategy but creates no immediate financial obligation or operating change
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.